Minerva Neurosciences (NERV) Shares Outstanding (Weighted Average) (2013 - 2026)

Minerva Neurosciences has reported Shares Outstanding (Weighted Average) for 14 years, with the latest figure at $43.9 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 480.0% year-over-year to $43.9 million; the trailing twelve-month figure through Mar 2026 stood at $43.9 million (up 480.0% YoY), and the FY2025 full-year result was $8.5 million, up 11.82% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $43.9 million, up from $8.5 million in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $43.9 million in Q1 2026, with the low at $5.3 million in Q1 2023.
• Historically, Shares Outstanding (Weighted Average) has averaged $8.9 million across 5 years, with a median of $7.6 million in 2023.
• Annual changes were most pronounced in 2022 — Shares Outstanding (Weighted Average) tumbled 87.5% — and 2026, when it jumped 480.0%.
• Minerva Neurosciences' Shares Outstanding (Weighted Average) stood at $5.3 million in 2022, then grew by 21.84% to $6.5 million in 2023, then increased by 16.33% to $7.6 million in 2024, then climbed by 11.82% to $8.5 million in 2025, then soared by 418.7% to $43.9 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $43.9 million (Q1 2026), $8.5 million (Q4 2025), and $7.6 million (Q3 2025), per Business Quant data.